October 27, 2017
The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 24 October 2017 and 25 October 2017, it purchased 75,000 and 109,460 ordinary shares of 1p each, respectively, in the capital of the Company ("Ordinary Shares") at an average price of 3.18p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 55,197,431 equivalent to 18.69% of Proteome Sciences' total issued share capital.
The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 55,197,431 Ordinary Shares of the Company representing 18.69% of the issued share capital of the Company.